Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026 Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131 Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast Cancer in 1Q ...

EL MONTE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Larry Wu, its Founder and Chief Executive Officer, will present at the 28th Annual Needham Growth Conference on Friday, January 16, 2026, at 2:15 p.m. ET/11:15 a.m. PT. The virtual presentation will be webcast at https://investors.gigacloudtech.com/ and will be available for replay ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, ...

核心财务表现 - 2025财年第四季度净亏损304.1万美元或每股亏损0.47美元，上年同期净亏损144.2万美元或每股亏损0.23美元 [1] - 2025财年全年净亏损1511.7万美元或每股亏损2.34美元，上年同期净亏损1660.8万美元或每股亏损2.56美元 [1] - 2025财年第四季度销售和服务收入为4546.7万美元，同比下降823.5万美元或15% [2] - 2025财年全年销售和服务收入为1.78554亿美元，同比下降803万美元或4% [2] 分地区销售表现 - 美洲地区第四季度销售额1823.4万美元，同比下降22%，全年销售额6860.4万美元，同比下降5% [3][4] - 欧洲地区第四季度销售额2347.5万美元，同比下降8%，全年销售额9086.3万美元，同比下降4% [3][5] - 亚太地区第四季度销售额375.8万美元，同比下降25%，全年销售额1908.7万美元，同比下降1% [3][7] 订单情况 - 2025财年第四季度新订单总额为4650.9万美元，同比下降456.8万美元或9% [8] - 2025财年全年新订单总额为1.7129亿美元，同比下降2701.2万美元或14% [8] - 美洲地区第四季度订单2200.3万美元，同比增长4%，但全年订单6914.8万美元，同比下降10% [9] - 欧洲地区第四季度订单2083.9万美元，同比下降13%，全年订单8156.9万美元，同比下降18% [10] - 亚太地区第四季度订单366.7万美元，同比下降39%，全年订单2057.3万美元，同比下降6% [11] 盈利能力与成本 - 2025财年第四季度毛利润为774.9万美元，毛利率为17%，上年同期毛利润1218.6万美元，毛利率23% [12] - 2025财年全年毛利润为3298万美元，毛利率为18%，上年同期毛利润3774.3万美元，毛利率20% [12] - 毛利率下降主要由于立式铣床整体销量下降、产品组合从高性能5轴机床转向3轴机床以及2025财年下半年美国进口商品关税增加导致销售成本上升 [12][13] - 2025财年第四季度销售、一般及行政费用为1120.7万美元，占销售额25%，全年为4324.8万美元，占销售额24% [14] 现金流与资产负债表 - 截至2025年10月31日，现金及现金等价物为4871.3万美元，较上年同期的3333万美元增加约1500万美元 [16] - 截至2025年10月31日，营运资本为1.73055亿美元，较上年同期的1.80788亿美元有所下降 [16] - 营运资本下降主要受存货和应收账款净额减少以及应付账款和衍生负债增加驱动 [16] - 公司无总债务，股东权益为1.98787亿美元 [21] 管理层评论与业务展望 - 首席执行官表示，美国和德国两大市场在本财年最后一个季度实现了年内最强的订单和销售表现，下半年订单和销售较上半年增长约5% [3] - 公司通过有针对性的领导层过渡加强了美国和德国团队，新领导层拥有深厚的行业经验并专注于执行、客户参与和增长 [3] - 公司在持续投资创新技术的同时，实现了销售、一般及行政费用同比减少近300万美元 [3] - 管理层认为，凭借强劲的资产负债表、更强大的管理团队和支持长期增长的产品组合，公司已做好准备应对周期 [3] 业务与市场描述 - 公司是一家国际工业技术公司，向全球金属切削和金属成型行业销售三个品牌的计算机数控机床 [17] - 旗下Hurco和Milltronics品牌机床配备具有专有软件的交互式控制系统，Takumi品牌机床配备由第三方生产的工业控制系统 [17] - 公司还生产高价值机床部件和附件，并提供可与任何机床集成的自动化解决方案 [17] - 终端市场包括独立加工车间、大型企业中的小批量制造业务以及生产型制造商 [17] - 客户为航空航天、国防、医疗设备、能源、运输和计算机设备等行业制造精密零件、工具、模具 [17] - 制造业务位于台湾、意大利和美国，通过直销和间接销售队伍在美洲、欧洲和亚洲销售产品 [17]

TAIPEI, Taiwan and MILPITAS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion” or the “Company”), a global leader in NAND flash controllers for solid state storage devices, plans to release its fourth quarter 2025 financial results after the market closes on February 3, 2026 and will host a conference call on February 4 at 8:00 a.m. Eastern Time. Participants must pre-register using the link below to participate in the live call. CONFERENCE CA ...

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient enrolled in RUBENS Phase 3 trial of obicetrapib and obicetrapib/ezetimibe fixed dose combo (FDC) in patients with metabolic syndrome -- -- Year-end cash, cash equivalents and marketable securities balance of approximately $729 million (unaudited) -- NAARDEN, the Netherlands and MIAMI, Jan. 09, 2 ...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused o ...

BERKELEY, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that it is revising its roadmap and adjusting the date for general availability of its 108-qubit quantum computing system, Cepheus™-1-108Q. Cepheus-1-108Q is now expected to reach general availability around the end of the first quarter of 2026. “While we are making strong progress with Cepheus-1-108Q, we are taking more ...

Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. These promotions reinforce TOI’s continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mis ...

TORONTO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today announced the preliminary results of its substantial issuer bid (the “SIB”), pursuant to which Altus Group offered to purchase for cancellation a number of its common shares (“Shares”) for an aggregate purchase price not to exceed C$350 million at a purchase price of not less than C$50.00 and not more than C$57.00 per Share. The SIB expired at 5: ...